Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DPYD antisense RNA 2 (DPYD-AS2) is a long non-coding, natural antisense RNA gene located in the DPYD genomic locus. It is processed in two or three transcript variants on the forward DNA strand and does not encode a protein. DPYD-AS2 is part of a complex regulatory RNA network that modulates DPYD gene expression at the transcriptional and possibly post-transcriptional level. The DPYD gene encodes dihydropyrimidine dehydrogenase, a key enzyme for pyrimidine and chemotherapeutic drug metabolism. Disorders in DPYD regulation—potentially mediated by antisense RNAs like DPYD-AS2—can contribute to disease phenotypes such as enzyme deficiency and severe adverse drug reactions to fluoropyrimidines. While antisense RNAs in general are being investigated as cancer therapy targets, DPYD-AS2 itself is not yet a therapeutic target but represents a candidate for research into regulatory mechanisms and disease-modifying effects.
Antisense RNA-mediated regulation of DPYD gene expression, possibly affecting enzyme levels and drug metabolism
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DPYD antisense RNA 2 (non-protein coding) (DPYD-AS2).